Patent search cpc:"A61K47/6891" Page 1

1.

发明授权
GRP78-binding antibodies and uses thereof and selection of phage-displayed accessible recombinant targeted antibodies 有权

公开(公告)号：US12060415B2

公开(公告)日：2024-08-13

申请号：US17592828

申请日：2022-02-04

Applicant: Rutgers, The State University of New Jersey

Inventor： Renata Pasqualini , Wadih Arap , Fernanda Iamassaki Staquicini , Fortunato Ferrara , Sara D'Angelo , Andrew R. M. Bradbury

IPC: C07K16/18 , A61K39/395 , A61P35/00 , C07K16/30 , G01N33/574 , A61K38/07 , A61K39/00 , A61K47/68 , A61K49/00 , C07K14/47 , C07K16/00 , C07K16/28 , C12N15/10 , C12N15/64 , C12Q1/6869 , G01N33/50

CPC classification number: C07K16/18 , A61K39/3955 , A61K39/39558 , A61P35/00 , C07K16/30 , C07K16/3023 , G01N33/574 , A61K38/07 , A61K2039/505 , A61K47/6803 , A61K47/6817 , A61K47/6843 , A61K47/6849 , A61K47/6891 , A61K49/0008 , C07K14/47 , C07K16/005 , C07K16/28 , C07K16/2866 , C07K2317/21 , C07K2317/35 , C07K2317/55 , C07K2317/622 , C07K2317/73 , C07K2317/77 , C12N15/1037 , C12N15/64 , C12N2810/00 , C12Q1/6869 , G01N33/5011 , G01N33/57423

Abstract: Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.

2.

发明公开
Bi-Specific Fusion Proteins 审中-公开

公开(公告)号：US20240101713A1

公开(公告)日：2024-03-28

申请号：US18483308

申请日：2023-10-09

Applicant: Silver Creek Pharmaceuticals, Inc.

Inventor： Ulrik Nielsen , Thomas Wickham , Birgit Schoeberl , Brian Harms , Bryan Linggi , Matthew Onsum , Byron DeLaBarre , Shaun M. Lippow

IPC: C07K16/46 , A61K45/06 , A61K47/66 , A61K47/68 , B82Y5/00 , C07K14/47 , C07K14/475 , C07K14/485 , C07K14/65 , C07K16/44 , C12N15/62

CPC classification number: C07K16/46 , A61K45/06 , A61K47/66 , A61K47/6811 , A61K47/6891 , B82Y5/00 , C07K14/47 , C07K14/475 , C07K14/485 , C07K14/65 , C07K16/44 , C12N15/62 , A61K38/00 , C07K2319/00

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

3.

发明公开
CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS 审中-公开

公开(公告)号：US20240067756A1

公开(公告)日：2024-02-29

申请号：US18206937

申请日：2023-06-07

Applicant: YALE UNIVERSITY

Inventor： David Spiegel , Ryan Murelli , Andrew Zhang

IPC: C07K16/44 , A61K9/00 , A61K31/4192 , A61K45/06 , A61K47/54 , A61K47/55 , A61K47/64 , A61K47/68 , C07D249/04 , C07K16/30

CPC classification number: C07K16/44 , A61K9/0019 , A61K31/4192 , A61K45/06 , A61K47/54 , A61K47/549 , A61K47/55 , A61K47/646 , A61K47/68 , A61K47/6803 , A61K47/6869 , A61K47/6873 , A61K47/6891 , C07D249/04 , C07K16/3069 , C07K2317/31

Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.

4.

发明公开
Bi-Specific Fusion Proteins 审中-公开

公开(公告)号：US20230322951A1

公开(公告)日：2023-10-12

申请号：US18311306

申请日：2023-05-03

Applicant: Silver Creek Pharmaceuticals, Inc.

Inventor： Ulrik Bjerl Nielsen , Thomas Wickham , Birgit Schoeberl , Brian Harms , Bryan Linggi , Matthew Onsum , Byron DeLaBarre

IPC: C07K16/46 , B82Y5/00 , C07K14/475 , C12N15/62 , A61K47/66 , A61K47/68 , A61K45/06 , C07K14/47 , C07K14/485 , C07K14/65 , C07K16/44

CPC classification number: C07K16/46 , B82Y5/00 , C07K14/475 , C12N15/62 , A61K47/66 , A61K47/6811 , A61K47/6891 , A61K45/06 , C07K14/47 , C07K14/485 , C07K14/65 , C07K16/44 , C07K2319/00 , A61K38/00

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.

5.

发明授权
Photo-controlled removal of targets in vitro and in vivo 有权

公开(公告)号：US11781955B2

公开(公告)日：2023-10-10

申请号：US17026724

申请日：2020-09-21

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services

Inventor： Hisataka Kobayashi , Peter Choyke , Martin John Schnermann

IPC: G01N1/44 , A61K47/68 , A61K49/00 , A61K41/00 , A61N5/06 , G01N1/40 , G01N33/50

CPC classification number: G01N1/44 , A61K41/0071 , A61K47/6891 , A61K49/0036 , A61N5/062 , G01N1/405 , G01N33/5002 , A61N2005/0651 , A61N2005/0663

Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.

6.

发明公开
Compositions and Methods for Treating Neurological-associated Disorders 审中-公开

公开(公告)号：US20230293722A1

公开(公告)日：2023-09-21

申请号：US18093775

申请日：2023-01-05

Applicant: MetaQor LLC

Inventor： Franco Vitaliano , Gordana Vitaliano

IPC: A61K47/69 , A61K9/51 , A61P31/18 , A61P25/28 , A61K47/68 , A61K31/496 , A61K31/195 , A61K31/137 , A61K31/7076 , A61K31/4458 , A61K31/437 , A61K31/55 , A61K31/165 , A61K31/485 , A61K31/27 , A61K31/357 , A61K49/08

CPC classification number: A61K47/6931 , A61K9/5169 , A61P31/18 , A61P25/28 , A61K47/6891 , A61K31/496 , A61K31/195 , A61K31/137 , A61K31/7076 , A61K31/4458 , A61K31/437 , A61K31/55 , A61K31/165 , A61K31/485 , A61K31/27 , A61K31/357 , A61K47/6801 , A61K49/085 , A61K49/08

Abstract: Compositions comprising clathrin nanoparticles and methods for treating neurological-associated disorders.

7.

发明授权
Anti-ROR2 antibodies 有权

公开(公告)号：US11673957B2

公开(公告)日：2023-06-13

申请号：US15555036

申请日：2016-03-10

Applicant: EUREKA THERAPEUTICS, INC. , MEMORIAL SLOAN-KETTERING CANCER CENTER

Inventor： Cheng Liu , Su Yan , Pei Wang , Nai-Kong Cheung , Hongfen Guo , Ming Cheng

IPC: C07K16/18 , C07K16/28 , A61K47/68 , C07K16/22 , A61K39/00

CPC classification number: C07K16/2857 , A61K47/6891 , C07K16/22 , C07K16/2803 , A61K2039/505 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/622 , C07K2317/732 , C07K2317/92 , C07K2317/94

Abstract: The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.

8.

发明授权
Bi-specific fusion proteins 有权

公开(公告)号：US09982060B2

公开(公告)日：2018-05-29

申请号：US14187728

申请日：2014-02-24

Applicant: Merrimack Pharmaceuticals, Inc.

Inventor： Ulrik Bjerl Nielsen , Thomas Wickham , Birgit Schoeberl , Brian Harms , Bryan Linggi , Matthew Onsum , Byron DeLaBarre

IPC: A61K38/18 , C07K14/47 , C07K16/44 , B82Y5/00 , C07K14/475 , C12N15/62 , A61K45/06 , C07K16/46 , C07K14/485 , C07K14/65 , A61K47/48 , A61K47/66 , A61K47/68 , A61K38/00

CPC classification number: C07K16/44 , A61K38/00 , A61K45/06 , A61K47/66 , A61K47/6811 , A61K47/6891 , B82Y5/00 , C07K14/47 , C07K14/475 , C07K14/485 , C07K14/65 , C07K16/46 , C07K2317/31 , C07K2317/76 , C07K2319/00 , C07K2319/80 , C12N15/62

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.